Jubilant records overall 21% growth, Q4 results decline in profits

While the Jubilant Life Sciences operations income rose 21 percent to Rs 5,161 crore in FY 2013, the consolidated profit after tax (PAT), declined 20.48 percent to Rs 66 crore in Q4 over its financial performance in the previous year

jubl-365

The board of Jubilant Life Sciences, an integrated pharmaceutical and life science company met on May 07, 2013, to approve financial results for the quarter and year ended March 31, 2013. As per the statement issued by the company after the meeting, the consolidated profit after tax (PAT), excluding extraordinary items, declined 20.48 percent to Rs 66 crore in Q4 March 2013 over Q4 March 2012. Income from operations rose 18 percent to Rs 1,392 crore in Q4 March 2013 over Q4 March 2012. Earnings before interest, taxation, depreciation and amortization (EBITDA) stood at Rs 244 crore in Q4 March 2013. EBITDA margin stood at 17.5 percent in Q4 March 2013.

Jubilant Life Sciences' consolidated (PAT), excluding extraordinary items, rose 5 percent to Rs 382 crore in FY 2013 over FY 2012. Income from operations rose 21 percent to Rs 5,161 crore in FY 2013 over FY 2012. EBITDA grew 18 percent to Rs 1,055 crore year-on-year (YoY) with EBITDA margin at 20.4 percent in FY 2013.

For FY2013 income from operations of pharmaceutical segment was Rs 2,658 crore, higher by 22 percent YoY with 52 percent share in the revenue mix. Segment EBITDA was Rs 750 crore, up 30 percent as compared to Rs 578 crore in the previous year. EBITDA margins were high at 28.2 percent as compared to 26.6 percent last year. Pharmaceutical segment comprises of APIs, generics, speciality pharma, CMO, DDDS and healthcare.

The life science ingredient segment stood at Rs 702 crore, higher by 13 percent YoY, and contributed 50 percent to the revenue mix. The segment EBITDA stood at Rs 175 crore with EBITDA margins at 24.9 percent compared to 29.7 percent in corresponding period. In FY2013, income from operations of this segment stood at Rs 2,503 crore, higher by 19 percent YoY with 48 percent contribution to overall revenues. Segmental EBITDA was Rs 382 crore, as against Rs 347 crore last year with EBITDA margins at 15.3 percent.

Income from life science ingredient operations in Q4 FY2013, was Rs 690 crore, up by 24 percent YoY and contributed 50 percent share to overall revenues. The segment EBITDA was Rs 95 crore, up 95 percent due to better capacity utilization from newly set up plants. The EBITDA margins at 13.8 percent as compared to 8.8 percent last year were up over 500 basis points.

 

Previous 1 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

GST

GST: Boon or Bane for Healthcare?

Send this article by email

X